drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Genetically engineered natural killer (NK) cells expressing a chimeric antigen receptor that targets CD123 (IL-3 receptor alpha) on tumor cells to trigger NK-mediated cytotoxicity against CD123-positive malignancies (e.g., AML, BPDCN). Administered as intravenous infusions with dose-escalation by CAR+ cells/kg.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Receptors, Chimeric Antigen
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Genetically engineered natural killer cells expressing a CD123-specific chimeric antigen receptor bind IL-3Rα (CD123) on tumor cells, activating NK effector signaling to induce targeted cytotoxicity via perforin/granzyme release, death-receptor pathways, and cytokine-mediated killing of CD123-positive malignant cells (e.g., AML, BPDCN).
drug_name
Anti-CD123 CAR-NK cells
nct_id_drug_ref
NCT06690827